PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STS
Pembrolizumab Alone and in Combination(s) With MK-0482 and MK-4830 Via Intratumoral Injection in Patients With Head and Neck Squamous Cell Carcinoma or Soft Tissue Sarcoma Prior to Planned Surgical Intervention
Sponsor: Merck Sharp & Dohme LLC
A EARLY_PHASE1 clinical study on Head and Neck Squamous Cell Carcinoma and Soft Tissue Sarcoma, this trial is completed. The trial is conducted by Merck Sharp & Dohme LLC and has accumulated 4 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
4 versions recorded-
Sep 2025 — Present [monthly]
Completed EARLY_PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed EARLY_PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed EARLY_PHASE1
-
Jun 2024 — Jul 2024 [monthly]
Completed EARLY_PHASE1
First recorded
Jun 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Merck Sharp & Dohme LLC
- Presage Biosciences
For direct contact, visit the study record on ClinicalTrials.gov .